Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751751 | 0.79 | SLC6A2 (0.52) | RAB9ATSHRCYP3A4LMNA | |
| SCHEMBL5675954 | 0.76 | CYP2D6 (0.34) | MTORRAB9AGRM7TSHRLMNA | |
| SCHEMBL5564914 | 0.76 | HSD17B10 (0.44) | CYP3A4ALOX15LMNACYP2D6 | |
| SCHEMBL5675447 | 0.76 | TSHR (0.44) | MTORRAB9AGRM7TSHRLMNA | |
| SCHEMBL17316084 | 0.76 | DPP4 (0.44) | LMNACYP2D6DPP4F2 | |
| SCHEMBL834442 | 0.76 | HSD17B10 (0.44) | CYP3A4ALOX15LMNACYP2D6 | |
| SCHEMBL2074934 | 0.76 | HSD17B10 (0.44) | CYP3A4ALOX15LMNACYP2D6 | |
| SCHEMBL27660991 | 0.75 | MTOR (0.46) | MTORRAB9AGRM7TSHRCYP3A4 | |
| SCHEMBL3449112 | 0.75 | MTOR (0.46) | MTORRAB9AGRM7TSHRCYP3A4 | |
| SCHEMBL8805729 | 0.73 | SRC (0.46) | LMNACYP2D6SRCHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410986-B2 | 4-6-diphenyl pyridine derivatives as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 2008-08-12 | — | — | US | claimed |
| EP-1912646-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | Bayer HealthCare AG (DE) | 2008-04-23 | — | — | EP | claimed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | claimed |
| US-20040097563-A1 | 4-6-Diphenyl pyridine derivatives as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | claimed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | claimed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| EP-1339687-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | claimed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | claimed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | claimed |
| WO-2002044153-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | WO | claimed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | claimed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0641356-B1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC (US) | 1998-04-22 | — | — | EP | claimed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | claimed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | claimed |
| US-4438136-A | INHIBITION OF THROMBOXANE ACTIVITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-20 | — | — | US | claimed |
| EP-0013608-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-06-15 | — | — | EP | claimed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| WO-2017061534-A1 | DIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2017-04-13 | — | — | WO | disclosed |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3129370-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9540359-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| WO-2016054804-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054806-A1 | SUBSTITTUED PYRIDINE INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054805-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015156421-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2912035-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014065434-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-05-01 | — | — | WO | disclosed |
| US-7902179-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-2042502-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1544199-B1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7410986-B2 | 4-6-diphenyl pyridine derivatives as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 2008-08-12 | — | — | US | disclosed |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1912646-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | Bayer HealthCare AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| EP-1805168-A1 | PROCESS FOR PREPARING SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS | Theravance, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7211572-B2 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006050025-A1 | PROCESS FOR PREPARING SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1650189-A1 | BENZYLAMINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1633707-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| WO-2005003090-A1 | 1- (ALKYLAMINOALKYL-PYROLIDIN-/PIPERIDINYL) -2, 2-DIPHENYLACETAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040147546-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040097563-A1 | 4-6-Diphenyl pyridine derivatives as antiinflammatory agents | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1396493-A1 | HETEROCYCLIC COMPOUNDS | Ajinomoto Co., Inc. (JP) | 2004-03-10 | — | — | EP | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| EP-1339687-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0826681-B1 | EPOXYSUCCINIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO (JP) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002044153-A1 | 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
| EP-1105133-A4 | TRICYCLIC COMPOUNDS | MERCK & CO INC (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1105133-A1 | TRICYCLIC COMPOUNDS | Merk & Co., Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1091760-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ESTER OR AMIDE PLA2 INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| US-6048869-A | REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-2000006167-A1 | TRICYCLIC COMPOUNDS | MERK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000000220-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ESTER OR AMIDE PLA2 INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
| US-6004954-A | TREATING GRAFT-VERSUS-HOST DISEASE AND AUTOIMMUNE DISEASES; ANTIALLERGENS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0741697-B1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5843992-A | Epoxysuccinic acid derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5807875-A | OBESITY THERAPY | DR. KARL THOMAE GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| EP-0641356-B1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC (US) | 1998-04-22 | — | — | EP | disclosed |
| EP-0826681-A1 | EPOXYSUCCINIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0795557-A1 | Condensed thiazine derivatives their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-5633364-A | N4 -substituted 2'-deoxycytidine compounds, oligonucleotides including N4 -labeled 2'-deoxycytidines, and a process for making oligonucleotides with N-modified 2'-deoxycytidines | AMOCO CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5543406-A | TREATING ANDROGEN RESPONSIVE OR MEDIATED DISEASE | GLAXO WELLCOME, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5523410-A | Intermediate for synthesis and production of amino acid derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| US-5491132-A | HYPOTENSIVE AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| EP-0648747-A1 | NOVEL INTERMEDIATE FOR SYNTHESIS AND PRODUCTION OF AMINO ACID DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5405950-A | N4 -substituted cytidines and process for incorporation into an oligonucleotides | AMOCO CORPORATION (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0641356-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO WELLCOME INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994025062-A1 | ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING RENIN INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-10 | — | — | WO | disclosed |
| EP-0300189-B1 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0617622-A1 | USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-05 | — | — | EP | disclosed |
| EP-0573652-A1 | REMEDY FOR RENAL DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993012796-A1 | USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| WO-1993013124-A1 | INHIBITORS OF 5-ALPHA-TESTOSTERONE REDUCTASE | GLAXO INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0441226-A1 | (cyanomethyl)pyridines useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1991-08-14 | — | — | EP | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | MTOR 1381/4885RAB9A 2207/4885GRM7 3990/4885 |
| US-20040097563-A1 | 4-6-Diphenyl pyridine derivatives as antiinflammatory agents | IL6, HRH4, CXCR6 | MTOR 2612/4885RAB9A 3676/4885GRM7 2087/4885 |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | MTOR 655/4885RAB9A 3984/4885GRM7 3944/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | MTOR 655/4885RAB9A 3984/4885GRM7 3944/4885 |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | MTOR 3681/4885RAB9A 2112/4885GRM7 3404/4885 |
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | MTOR 2010/4885RAB9A 965/4885GRM7 2944/4885 |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | MTOR 2852/4885RAB9A 819/4885GRM7 1823/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | MTOR 3888/4885RAB9A 3172/4885GRM7 2758/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | MTOR 655/4885RAB9A 3984/4885GRM7 3944/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | MTOR 1381/4885RAB9A 2207/4885GRM7 3990/4885 |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | DNTT, PNP, NNMT | MTOR 1225/4885RAB9A 3071/4885GRM7 3948/4885 |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | MTOR 3175/4885RAB9A 2981/4885GRM7 1880/4885 |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | MTOR 3175/4885RAB9A 2981/4885GRM7 1880/4885 |
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MTOR 1556/4885RAB9A 3076/4885GRM7 1468/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | MTOR 2714/4885RAB9A 825/4885GRM7 1769/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | MTOR 3049/4885RAB9A 904/4885GRM7 1795/4885 |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | KCNAB1, BDKRB2, ARRB1 | MTOR 3133/4885RAB9A 1811/4885GRM7 1170/4885 |
| US-20040147546-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | TNF, LITAF, NOD2 | MTOR 430/4885RAB9A 4080/4885GRM7 4037/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MTOR 2122/4885RAB9A 3507/4885GRM7 1517/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | MTOR 249/4885RAB9A 965/4885GRM7 2623/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | MTOR 1665/4885RAB9A 1895/4885GRM7 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.